Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($3.07), $0.37 better than the analyst estimate of ($3.44). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $5.17 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Southland Holdings (SLND) Misses Q2 EPS by 122c
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance